Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H F Schran

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Clinical Therapeutics|January 1, 1985
Bioavailability of ergoloid mesylates liquid capsuleH F Schran
Journal of Pharmaceutical Sciences|November 1, 1979
Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassayL J Loeffler, H F Schran
International Journal of Clinical Pharmacology, Therapy, and Toxicology|January 1, 1985
Pharmacokinetics of dihydroergotamine following subcutaneous administration in humansH F Schran, F L Tse
Biopharmaceutics & Drug Disposition|July 1, 1988
Pharmacokinetics and bioavailability of ergoloid mesylatesH F Schran, S McDonald, R Lehr
Obstetrics and Gynecology|March 1, 1989
Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapyE Katz, H F Schran, E Y Adashi
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1994
Pharmacokinetics and metabolism of cyclosporin G in humansJ B Mangold, H F Schran, F L Tse
Biopharmaceutics & Drug Disposition|July 1, 1985
Pharmacokinetics and pharmacodynamics of bromocriptine in the ratH F Schran, F L Tse, S I Bhuta
Progress in Allergy|January 1, 1986
Cyclosporin. Bioanalytical considerationsH F Schran, W T Robinson, E Abisch, et al.
The American Journal of Medicine|November 1, 1984
Acquired immune deficiency syndrome. No evidence of the presence of cyclosporineH F Schran, A E Hassel, J Raskova, et al.
Thrombosis Research|July 1, 1983
The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combinationH F Schran, D W Bitz, F J DiSerio, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Clinical Therapeutics|January 1, 1985
Bioavailability of ergoloid mesylates liquid capsuleH F Schran
Journal of Pharmaceutical Sciences|November 1, 1979
Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassayL J Loeffler, H F Schran
International Journal of Clinical Pharmacology, Therapy, and Toxicology|January 1, 1985
Pharmacokinetics of dihydroergotamine following subcutaneous administration in humansH F Schran, F L Tse
Biopharmaceutics & Drug Disposition|July 1, 1988
Pharmacokinetics and bioavailability of ergoloid mesylatesH F Schran, S McDonald, R Lehr
Obstetrics and Gynecology|March 1, 1989
Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapyE Katz, H F Schran, E Y Adashi
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1994
Pharmacokinetics and metabolism of cyclosporin G in humansJ B Mangold, H F Schran, F L Tse
Biopharmaceutics & Drug Disposition|July 1, 1985
Pharmacokinetics and pharmacodynamics of bromocriptine in the ratH F Schran, F L Tse, S I Bhuta
Progress in Allergy|January 1, 1986
Cyclosporin. Bioanalytical considerationsH F Schran, W T Robinson, E Abisch, et al.
The American Journal of Medicine|November 1, 1984
Acquired immune deficiency syndrome. No evidence of the presence of cyclosporineH F Schran, A E Hassel, J Raskova, et al.
Thrombosis Research|July 1, 1983
The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combinationH F Schran, D W Bitz, F J DiSerio, et al.
Pageof 3